0.05Open0.05Pre Close0 Volume939 Open Interest1.00Strike Price0.00Turnover445.32%IV123.40%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2993Delta0.9130Gamma9.40Leverage Ratio-0.0055Theta0.0000Rho2.81Eff Leverage0.0003Vega
Relmada Therapeutics Stock Discussion
Dow Jones· 5 mins ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance
No comment yet